louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06541912: Comparative Evaluation of Implant Stability, Soft & Hard Tissue Healing Around UV Activated vs Conventional Implants
Official title: Comparative Evaluation of Implant Stability, Soft and Hard Tissue Healing Around UV Activated Versus Conventional Implants - A Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: UV Dental Implant
Keywords: Dental Implants
Lead sponsor: Krishnadevaraya College of Dental Sciences & Hospital
Sponsor class: OTHER
First posted: 2024-08-07
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Research is to compare and evaluate the primary and secondary implant stability, healing of the soft tissue around UV activated implants and conventional implants.

Detailed description: Research is to compare and evaluate the primary and secondary implant stability, healing of the soft tissue around UV activated implants and conventional implants. The objectives are to access the primary and secondary implant stability using Resonance frequency analysis, marginal bone level using RVG with grid, healing of the soft tissue. The control group will be treated with conventional implant and test group will be treated with UV implants. The total number of participants are 12 and 24 sites (control - 12 sites, test - 12 sites) with 3 months follow up.

Eligibility criteria: Inclusion Criteria:

* At east above 18 years of age
* Patients who needs replacement for at least 2 missing teeth in the posterior region of mandible
* Adequate bone volume to accommodate planned dental implants
* Patients who will comply with oral health care instructions and necessary visits

Exclusion Criteria:

* General contraindications to dental implant treatment ( uncontrolled diabetes, severe cardiovascular or infectious disease)
* Intravenous and oral bisphosphonate therapy
* Unwillingness to return for the follow up examinations
* Smokers
* Patients who are psychologically unable to participate
* Poor oral hygiene

Primary outcomes:
measure: Implant stability using Resonance Frequency Analysis
timeFrame: "Immediately after Post-operative", "1 month", "3 months"
Secondary outcomes:
measure: Marginal bone loss using RVG with grid
timeFrame: "Immediately after Post-operative", 3 months
measure: Soft tissue healing
timeFrame: 1 week, 1 month, 3 months.
Other outcomes:
Locations:
city: Bengaluru
country: India
facility: Dr. Prabhuji MLV
state: Karnataka
Study officials:
References:
Clinical trial NCT00759512: Effects of Therapeutic Touch on Osteoarthritis of the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis in the Knee
Lead sponsor: University of Toledo
Sponsor class: OTHER
First posted: 2008-09-25
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is to evaluate the efficacy of the Kreiger/Kunz method of Therapeutic Touch on function, pain perception and quality of life in persons with Osteoarthritis in the knee.


Eligibility criteria: Inclusion Criteria:

* Persons diagnosed with or exhibiting signs of osteoarthritis of at least one knee.

Exclusion Criteria:

* Persons with connective tissue disorder
* Persons with bilateral total joint replacement of the knee
* Persons with dementia
* Persons with a systemic illness producing joint symptoms

Primary outcomes:
measure: SF36
timeFrame: 8, 12, 16 weeks
measure: WOMAC
timeFrame: 8, 12 and 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Toledo
country: United States
facility: University of Toledo, Health Science Campus
state: Ohio
Study officials:
affiliation: UT, Health Science Campus
name: Ann Smith, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02770846: Immediate Loading Versus Delayed Loading in Single-implant
Official title: Evaluation of Immediate Loading Versus Delayed Loading in Single-implant Restorations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Immediate Dental Implant Loading
Lead sponsor: Folktandvården Skåne AB
Sponsor class: OTHER
First posted: 2016-05-12
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this prospective randomized clinical study was to compare implant survival, patient satisfaction, and radiographic, clinical, and aesthetic outcomes following immediate loading (IL) and delayed loading (DL) of single dental implants after 1,3 and 5 years of follow-up.

Detailed description: Purpose: The objective of the present prospective randomized clinical study was to compare the overall treatment outcome following immediate loading (IL) and delayed loading (DL) of single implants after 5 year of follow-up.

Patients with a missing maxillary tooth (15-25) were randomly assigned to IL or DL. The protocol included implant installation in healed sites, immediate loading, delayed loading, temporary screw-retained restoration, and replacement with a permanent single implant crown. Outcome measures were implant survival, marginal bone level, soft tissue changes, papillae index, pink, and white esthetic score (PES and WES), patient judged aesthetics, and oral health impact profile (OHiP-14).

Eligibility criteria: Inclusion Criteria:

* Patients of at least 18 years of age.
* In need of one or more single-tooth replacements.
* The single-tooth replacement needs to be in the anterior maxilla
* Minimum of mesial-distal width of interdental space of 6 mm

Exclusion Criteria:

* General contraindications for oral surgery
* Inadequate oral hygiene
* Insufficient bone volume at the recipient site

Primary outcomes:
measure: Change in Level of Marginal Bone
timeFrame: Baseline to 12 months
measure: Pink Esthetic Score
timeFrame: After 12 months
measure: Oral Health Impact Profile 14
timeFrame: Pre-surgery
measure: White Esthetic Score
timeFrame: Baseline
measure: Pink Esthetic Score
timeFrame: Baseline
measure: Oral Health Impact Profile 14 (OHIP-14)
timeFrame: After 12 months
measure: White Esthetic Score
timeFrame: After 12 months
measure: Change in Level of Marginal Bone
timeFrame: Baseline to 5 years
measure: Pink Esthetic Score
timeFrame: After 5 year
measure: White Esthetic Score
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Malmö
country: Sweden
facility: Centre of Dental Specialist Care
state: Scania
Study officials:
affiliation: Malmö University
name: Ann Wennerberg, DDS, Phd
role: STUDY_DIRECTOR
References:
Clinical trial NCT00043446: Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Ovarian Neoplasms
Lead sponsor: Tularik
Sponsor class: INDUSTRY
First posted: 2002-08-12
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.


Eligibility criteria: Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of ovarian cancer
* Subjects must have received 1-2 regimens of prior chemotherapy (with one containing paclitaxel)
* At least 18 years of age
* Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size.
* Karnofsky performance status of at least 70%
* Estimated life expectancy of at least 12 weeks
* Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive
* Subject must be able to comply with study procedures and follow-up examinations.
* Signed written informed consent
* Lab Values (obtained ≤ 7 days prior to study enrollment):
* ANC at least 1.5x10e9/L,
* Platelet count at least 100x10e9/L,
* Hemoglobin at least 8.5 g/dL,
* Creatinine within 2 times upper limit of normal
* AST and ALT within 3 times upper limit of normal
* Bilirubin within 1.5 times upper limit of normal
* Albumin great than 2.5 g/dL
* INR \< 1.5 for subjects without anticoagulants

Exclusion Criteria

* Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment
* NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of \<50%, or acute anginal symptoms
* Patients who have received any investigational agent within 4 weeks of enrollment
* Patients who are pregnant or breast-feeding
* History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
* History of central nervous system metastases or carcinomatous meningitis
* Major surgery within 4 weeks of enrollment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Health Center
state: California
city: Los Angeles
country: United States
facility: USC Women's and Children's Hospital
state: California
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Buffalo
country: United States
facility: Roswell Park Cancer Center
state: New York
Study officials:
affiliation: Tularik
name: Kerrie Boyd
role: STUDY_CHAIR
References:
Clinical trial NCT02872246: Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) - Assay
Official title: Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreen Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-08-19
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Evaluation of the effectiveness of a sunscreen product by determining its Sun Protection Factor (SPF) on the skin of human subjects.


Eligibility criteria: Inclusion Criteria:

* Male or female of an age of 18 to 70 years inclusive;
* Fitzpatrick Skin Type I, II and/or III for SPF testing;
* Good health as determined from the CRO Subject History Form (SHF);
* Signed and dated Informed Consent Form;
* Signed and dated Health Insurance Portability and Accountability Act (HIPAA) Form;
* An unambiguous minimal erythema dose (MED).

Primary outcomes:
measure: Evaluation of water resistant SPF
timeFrame: 16-24 hours post exposure
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01985646: A Trial on Conservative Treatment for Infants' Hirschsprung Disease
Official title: A Prospective, Randomized Controlled Trial of Conservative Versus Surgery Treatment of Normal and Short-segment Hirschsprung Disease for Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Hirschsprung Disease
Keywords: Hirschsprung disease
conservative treatment
surgery treatment
infants
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2013-11-15
Enrollment: 48
Sex: ALL
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study was designed to compare the efficacy of conservative treatment to operative treatment for improvement of constipation symptoms in infants with short or normal-segment Hirschsprung disease.


Eligibility criteria: Inclusion Criteria:

* Hard or firm stools for twice or less per week
* Age were from newborn to 3 months
* Histochemical acetylcholinesterase reaction (AChE) in rectal mucosa was positive
* The narrowed distal bowel on barium enema was characterized as normal or short-segment Hirschsprung disease with a 24h barium retention

Exclusion Criteria:

* Children \>3months of age
* Patients presented severe inflammation or malnutrition, unconsciousness, and symptoms of a ruptured hollow viscus
* Barium enema showed long-segment or total colonic aganglionic bowel

Primary outcomes:
measure: the change of defecation frequence
timeFrame: 6~12 months
Secondary outcomes:
measure: stool pattern
timeFrame: 6~12 months
measure: controlling defecation ability
timeFrame: 6~12 months
measure: complications
timeFrame: 6~12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00993746: 2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula
Official title: Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Infraclavicular Brachial Plexus Block
Keywords: Ultrasound guided infraclavicular brachial plexus block
Bupivacaine
Bupivacaine plus lidocaine
End stage renal disease
Arteriovenous fistula
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2009-10-12
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Will the technique of adding lidocaine to bupivacaine fasten the onset of bupivacaine alone for infraclavicular brachial plexus block in end-stage renal disease (ESRD) patient?


Eligibility criteria: Inclusion Criteria:

* ESRD patient for AVF procedure
* age \>17 year
* BMI 20-35 kg/m2
* communicable

Exclusion Criteria:

* BMI \> 35 kg/m2 BMI \< 20 kg/m2 หรือ BW \< 35 kg
* History of allergy to local anesthetic drugs
* Pre-operative neurological deficit, Neuromuscular disorder หรือ old CVA
* Psychiatric disorder
* Coagulation disorder
* Uncontrolled seizure
* Pregnant and lactating women

Primary outcomes:
measure: onset of sensory block
timeFrame: 24 hour
Secondary outcomes:
measure: onset of motor block
timeFrame: 24 hour
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Department of anesthesiology Siriraj Hospital Mahidol University
Study officials:
affiliation: Siriraj Hospital
name: Orawan Pongrawewan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01785446: Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System
Official title: Effect of Dexmedetomidine on Cisatracurium Infusion and Sufentanil Consumption and Its Variations in Different Age Groups, Using a Closed Loop Computer Controlled System.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: The Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.
Effect of Dexmedetomidine on Sufentanil Consumption.
Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups.
Keywords: Dexmedetomidine
Cisatracurion infusion
Sufentanil
Recovery Index
Closed loop computer control system
Lead sponsor: Tianjin Medical University General Hospital
Sponsor class: OTHER
Collaborators: name: Shehzaad Joomye
name: Haiyun Wang
name: Donglai Yan
First posted: 2013-02-07
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to:

* determine the effect of dexmedetomidine on cisatracurium infusion requirements and sufentanil consumption.
* analyze the cisatracurium infusion requirements and sufentanil consumption in different age groups.


Eligibility criteria: Inclusion Criteria:

* ASA status 1 and 2.
* Consent approval written and oral.
* Patients scheduled for elective abdominal surgery under general anesthesia.

Exclusion Criteria:

* Patients with neuromuscular disorders.
* Patients with history of stroke, flaccid paralysis or other neurological disorders.
* Significant renal, hepatic or cardiac dysfunction.
* Consent refusal.

Primary outcomes:
measure: Cisatracurium infusion consumption.
timeFrame: At the time of surgery
Secondary outcomes:
measure: Sufentanil consumption.
timeFrame: At the time of operation.
Other outcomes:
measure: Recovery Index
timeFrame: 30 minutes post-operative.
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
state: Tianjin
Study officials:
affiliation: Tianjin Medical University General Hospital
name: Guolin Wang, MD, PhD, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Joomye S, Yan D, Wang H, Zhou G, Wang G. Consumption of Cisatracurium in different age groups, using a closed loop computer controlled system. BMC Anesthesiol. 2014 Apr 21;14:29. doi: 10.1186/1471-2253-14-29. eCollection 2014.
Clinical trial NCT03929146: Liposomal Bupivacaine Versus Interscalene Nerve Block
Official title: Randomized Trial Comparing Interscalene Nerve Block to Liposomal Bupivacaine For Pain Management Following Reverse Total Shoulder Arthroplasty (RTSA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain, Postoperative
Lead sponsor: University of Cincinnati
Sponsor class: OTHER
First posted: 2019-04-26
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare two different pain management interventions in patients undergoing reverse total shoulder arthroplasty. The two interventions are 1) pre-operative interscalene nerve block and 2) intraoperative injection of liposomal bupivacaine (Exparel, Pacira Pharmaceuticals, Parsippany NJ). Specifically, the primary aims of this study are to compare these two interventions on the following: post-operative opioid consumption, pain scores, and patient satisfaction. Additionally, the investigators want to determine if psychological factors, catastrophizing and resilience, are associated with post-operative pain control and satisfaction. The investigators' hypothesis is that the two interventions will have similar pain control efficacy and that the liposomal bupivacaine group will experience faster post-operative recovery, earlier discharge, and improved satisfaction. The investigators also expect patient catastrophizing and resilience to significantly predict the degree of post-operative pain and level of patient satisfaction.


Eligibility criteria: Inclusion Criteria:

* patients who are older than 18 years
* patients undergoing reverse total shoulder arthroplasty

Exclusion Criteria:

* pregnancy
* inability to provide informed consent
* deemed unreliable for follow-up survey completion
* individuals who do not speak English
* those who have an allergy to the study medications (ropivicaine, bupivicaine) or have clinically significant hepatic disease

Primary outcomes:
measure: Opioid Consumption
timeFrame: 72 hours post-operatively
measure: Visual Analog Scale Pain Scores
timeFrame: 72 hours post-operatively
measure: Patient Satisfaction: Rating
timeFrame: 72 hours post-operatively
measure: Relationship between catastrophizing, pain, and patient satisfaction
timeFrame: Catastrophizing will be measured pre-operatively
measure: Relationship between resilience, pain, and patient satisfaction
timeFrame: Resilience will be measured pre-operatively
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: University of Cincinnati Medical Center
state: Ohio
Study officials:
affiliation: University of Cincinnati, Department of Orthopaedics and Sports Medicine
name: Adam Schumaier, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06349746: Cervical Unilateral Antero-posterior Mobilization and Thoracic Central Postro-anterior Mobilization in Treatment of Shoulder Impingement Syndrome
Official title: The Addition of Cervical Unilateral Antero-posterior Mobilization and Thoracic Central Postro-anterior Mobilization to Selected Therapeutic Exercise Program in Treatment of Shoulder Impingement Syndrome: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Shoulder Impingement
Lead sponsor: Egyptian Chinese University
Sponsor class: OTHER
Collaborators: name: Benha University
First posted: 2024-04-05
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: this study will be conducted to compare one group receiving selected therapeutic exercises and other group recieve cervical and thoracic mobilization added to selected therapeutic exercise Program on pain intensity, Pain-free shoulder flexion and scaption active ROM, muscle strength of external rotator and abductors, shoulder functional status in patients with Shoulder Impingement Syndrome.
Primary purpose: TREATMENT

Brief summary: Shoulder impingement syndrome (SIS) is a complex, multi-factorial problem that is treated with a variety of different conservative options. The conservative option that has shown effectiveness is manual therapy of the cervical and thoracic spine

Detailed description: This study will be conducted to answer the following question:

What is the effect of adding cervical and thoracic mobilization to selected therapeutic exercise Program on pain intensity, Pain-free shoulder flexion and scaption active ROM, muscle strength of external rotator and abductors, shoulder functional status in patients with Shoulder Impingement Syndrome

Eligibility criteria: Inclusion Criteria:

* • patients who had received at least two positive signs on their Neer sign, Hawkins sign, supraspinatus test, apprehension test, and relocation test

  * Patients report pain on elevating the arm between 70 ° and 120 ° (the "painful arc"), on forced movement above the head, and when lying on the affected side

Exclusion Criteria:

* • cervical radiculopathy

  * a history of shoulder surgery
  * corticosteroid injection within the past month
  * Subjects who had received physical therapy treatment for their shoulder within the past three months.

Primary outcomes:
measure: pain intensity
timeFrame: pre intervention and after 6 weeks of intervention
measure: shoulder flexion and abduction range of motion
timeFrame: pre intervention and after 6 weeks of intervention
measure: muscle strength
timeFrame: pre intervention and after 6 weeks of intervention
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Benha University
name: Noha Elserty
role: PRINCIPAL_INVESTIGATOR
References: